High molar activity [18F]tetrafluoroborate synthesis for sodium iodide symporter imaging by PET

Soloviev, D., Dzien, P., Mackintosh, A., Malviya, G. , Brown, G. and Lewis, D. (2022) High molar activity [18F]tetrafluoroborate synthesis for sodium iodide symporter imaging by PET. EJNMMI Radiopharmacy and Chemistry, 7, 32. (doi: 10.1186/s41181-022-00185-w) (PMID:36512196) (PMCID:PMC9747990)

[img] Text
286356.pdf - Published Version
Available under License Creative Commons Attribution.

2MB

Abstract

Background: Sodium iodide symporter (NIS) imaging by positron emission tomography (PET) is gaining traction in nuclear medicine, with an increasing number of human studies being published using fluorine-18 radiolabelled tetrafluoroborate ([18F]TFB). Clinical success of any radiotracer relies heavily on its accessibility, which in turn depends on the availability of robust radiolabelling procedures providing a radiotracer in large quantities and of high radiopharmaceutical quality. Results: Here we publish an improved radiolabelling method and quality control procedures for high molar activity [18F]TFB. The use of ammonium hydroxide for [18F]fluoride elution, commercially available boron trifluoride-methanol complex dissolved in acetonitrile as precursor and removal of unreacted [18F]fluoride on Florisil solid-phase extraction cartridges resulted in the reliable production of [18F]TFB on SYNTHRA and TRACERLAB FXFN automated synthesizers with radiochemical yields in excess of 30%, radiochemical purities in excess of 98% and molar activities in the range of 34–217 GBq/µmol at the end of synthesis. PET scanning of a mouse lung tumour model carrying a NIS reporter gene rendered images of high quality and improved sensitivity. Conclusions: A novel automated radiosynthesis procedure for [18F]tetrafluoroborate has been developed that provides the radiotracer with high molar activity, suitable for preclinical imaging of NIS reporter gene.

Item Type:Articles
Additional Information:The authors would like to acknowledge funding from Cancer Research UK for core funding to the CRUK Beatson Institute (A31827), to David Lewis’ laboratory (A25006) and to the CRUK Glasgow Centre (A25142), Beatson Cancer Charity and Beatson Endowment. We acknowledge generous support from the NHS Greater Glasgow & Clyde Endowment fund which facilitated this research by providing salary to DS.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Lewis, Dr David and Malviya, Dr Gaurav and Dzien, Dr Piotr
Authors: Soloviev, D., Dzien, P., Mackintosh, A., Malviya, G., Brown, G., and Lewis, D.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:EJNMMI Radiopharmacy and Chemistry
Publisher:SpringerOpen
ISSN:2365-421X
ISSN (Online):2365-421X
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in EJNMMI Radiopharmacy and Chemistry 7: 32
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
174115CRUK Centre RenewalOwen SansomCancer Research UK (CRUK)C7932/A25142CS - Beatson Institute for Cancer Research